{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:55:41Z","timestamp":1771001741171,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.mayocp.2022.03.010","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:20:10Z","timestamp":1660954810000},"page":"1824-1835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Indirect Comparison of Glucocorticoid-Sparing Agents for Remission Maintenance in Giant Cell Arteritis: A Network Meta-analysis"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4564-2931","authenticated-orcid":false,"given":"Sabine","family":"Mainbourg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Tabary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Cucherat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Gueyffier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Lobbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Aussedat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Grenet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Durieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Samson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Christophe","family":"Lega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.mayocp.2022.03.010_bib1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.autrev.2017.05.014","article-title":"Recent advances in our understanding of giant cell arteritis pathogenesis","volume":"16","author":"Samson","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2022.03.010_bib2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.revmed.2015.10.350","article-title":"Physiopathologie des vascularites primitives des gros vaisseaux","volume":"37","author":"Samson","year":"2016","journal-title":"Rev Med Interne"},{"issue":"3","key":"10.1016\/j.mayocp.2022.03.010_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.revmed.2015.12.015","article-title":"Management of giant cell arteritis: recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)","volume":"37","author":"Bienvenu","year":"2016","journal-title":"Rev Med Interne"},{"issue":"11","key":"10.1016\/j.mayocp.2022.03.010_bib4","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.mayocp.2022.03.010_bib5","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.23901","article-title":"Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: a meta-analysis","volume":"72","author":"Mainbourg","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.mayocp.2022.03.010_bib6","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","article-title":"Th17 and Th1 T-cell responses in giant cell arteritis","volume":"121","author":"Deng","year":"2010","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.mayocp.2022.03.010_bib7","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/art.34647","article-title":"Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.mayocp.2022.03.010_bib8","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.mayocp.2022.03.010_bib9","first-page":"495","article-title":"A\u00a0prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocp.2022.03.010_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"issue":"10031","key":"10.1016\/j.mayocp.2022.03.010_bib11","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mayocp.2022.03.010_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2022.03.010_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.mayocp.2022.03.010_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/03009742.2019.1571223","article-title":"Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis","volume":"48","author":"Turesson","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.mayocp.2022.03.010_bib16","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2020"},{"issue":"11","key":"10.1016\/j.mayocp.2022.03.010_bib17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mayocp.2022.03.010_bib19","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.mayocp.2022.03.010_bib20","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2022.03.010_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.mayocp.2022.03.010_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.mayocp.2022.03.010_bib23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11606-020-06330-y","article-title":"Making narrative statements to describe treatment effects","volume":"36","author":"Murad","year":"2021","journal-title":"J\u00a0Gen Intern Med"},{"issue":"4","key":"10.1016\/j.mayocp.2022.03.010_bib24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.mayocp.2022.03.010_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"issue":"7521","key":"10.1016\/j.mayocp.2022.03.010_bib26","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.mayocp.2022.03.010_bib28","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.mayocp.2022.03.010_bib29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A\u00a0double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Martinez-Taboada","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.mayocp.2022.03.010_bib30","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial","volume":"73","author":"Seror","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.mayocp.2022.03.010_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.mayocp.2022.03.010_bib32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.semarthrit.2017.12.009","article-title":"Treatments for giant cell arteritis: meta-analysis and assessment of estimates reliability using the fragility index","volume":"48","author":"Berti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.mayocp.2022.03.010_bib33","doi-asserted-by":"crossref","first-page":"rkaa017","DOI":"10.1093\/rap\/rkaa017","article-title":"Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients","volume":"4","author":"Regola","year":"2020","journal-title":"Rheumatol Adv Pract"},{"issue":"2 suppl 124","key":"10.1016\/j.mayocp.2022.03.010_bib34","first-page":"112","article-title":"Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice","volume":"38","author":"Calder\u00f3n-Goercke","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.mayocp.2022.03.010_bib35","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0003319717753223","article-title":"Tocilizumab in giant cell arteritis: a real-life retrospective study","volume":"69","author":"Vitiello","year":"2018","journal-title":"Angiology"},{"issue":"8","key":"10.1016\/j.mayocp.2022.03.010_bib36","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3899\/jrheum.151252","article-title":"Tocilizumab in giant cell arteritis: a multicenter retrospective study of 34 patients","volume":"43","author":"R\u00e9gent","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.mayocp.2022.03.010_bib37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.semarthrit.2019.01.003","article-title":"Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice","volume":"49","author":"Calder\u00f3n-Goercke","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.mayocp.2022.03.010_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40744-019-0139-5","article-title":"Adverse events in giant cell arteritis and rheumatoid arthritis patient populations: analyses of tocilizumab clinical trials and claims data","volume":"6","author":"Gale","year":"2019","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.mayocp.2022.03.010_bib39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejim.2018.06.008","article-title":"Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of giant cell arteritis: a prospective study","volume":"57","author":"Samson","year":"2018","journal-title":"Eur J Intern Med"},{"issue":"9","key":"10.1016\/j.mayocp.2022.03.010_bib40","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","article-title":"Risk of relapse after discontinuation of tocilizumab therapy in giant\u00a0cell arteritis","volume":"58","author":"Adler","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.mayocp.2022.03.010_bib41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12325-016-0295-8","article-title":"Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration","volume":"33","author":"Bianchi","year":"2016","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.mayocp.2022.03.010_bib42","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.mayocp.2022.03.010_bib43","article-title":"Individual participant data meta-analyses compared with meta-analyses based on aggregate data","volume":"9","author":"Tudur Smith","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2022.03.010_bib44","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A\u00a0randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.mayocp.2022.03.010_bib45","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","article-title":"Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial","volume":"54","author":"Mazlumzadeh","year":"2006","journal-title":"Arthritis Rheum"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622001872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622001872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:38:40Z","timestamp":1758418720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619622001872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0025619622001872"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.03.010","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indirect Comparison of Glucocorticoid-Sparing Agents for Remission Maintenance in Giant Cell Arteritis: A Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}